TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03341130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Oral Appliance
Description: Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
Study: NCT02215590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re-Step
Description: Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week.
Study: NCT04073095

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified-thoracolumbar interfascial plane block (Group T)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study: NCT01430585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502 in combination with Letrozole
Description: PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
Study: NCT02496780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novolog insulin
Description: 3x daily rapid-acting insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levemir insulin
Description: basal insulin once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once or 3x daily
Study: NCT02244333

Intervention type: DRUG
Intervention: ALNA®
Study: NCT01097837

Intervention type: OTHER
Intervention: Non-interventional
Description: This is an observational study conducted by anonymous survey. There is no intervention.
Study: NCT04528446

Intervention type: RADIATION
Intervention: Dual-energy X-ray absorptiometry
Description: DXA whole body, hip, spine, and radius at baseline, and 12-month visit.

Intervention type: RADIATION
Intervention: High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)
Description: HR-pQCT of the radius and tibia at baseline, and 12-month visit.

Intervention type: OTHER
Intervention: Blood draw and Urine collection
Description: The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
Study: NCT04388943

Intervention type: OTHER
Intervention: Observation
Description: Physiological Measurements Patient reported questionnaire Blood sampling
Study: NCT02756793

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Treatment
Description: May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm.
Study: NCT06357988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04430062

Intervention type: PROCEDURE
Intervention: Surgical procedures performed under general anesthesia
Description: Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
Study: NCT06357988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02983006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DS-8273a
Description: * Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 5 mg/kg IV Q 3 weeks
Study: NCT04593030

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference
Study: NCT03816423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
Study: NCT04593030

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban dispensing claim is used as the exposure
Study: NCT01307566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure CPAP
Description: CPAP treatment
Study: NCT03807427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READY-Nepal
Description: Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
Study: NCT03518008

Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses
Study: NCT04488328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
Description: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
Description: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
Description: patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
Study: NCT03892720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01110421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
Study: NCT03389646

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CERAMENT G V
Description: During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU).
Study: NCT02252627

Intervention type: DRUG
Intervention: Administration of phenylephrine
Description: Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.

Intervention type: OTHER
Intervention: Measurement of stroke volume
Description: The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor

Intervention type: OTHER
Intervention: Contrast enhanced ultrasound scan
Description: Microvascular blood flow will be measured using a contrast enhanced ultrasound scan

Intervention type: DRUG
Intervention: Administration of ephedrine
Description: Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
Study: NCT01252290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza™
Description: 4 capsules daily for 6 months
Study: NCT03384251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive sex education
Description: A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
Study: NCT00722917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-379
Description: TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT02310672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: All patients take open-label macitentan 10mg o.d.
Study: NCT04060329

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
Study: NCT00086580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluCAM [Fludara + Campath]
Description: Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
Study: NCT01217918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg
Description: 1 mg or placebo a material sparing tablet per day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg
Description: 5 mg or placebo as material sparing tablet per day for 10 days
Study: NCT01101269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI or ARB
Description: Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
Study: NCT01852669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inversion
Description: Patients inverted 30 degree head down in Trendelenburg position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy
Description: Shock wave lithotripsy
Study: NCT01217918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg
Description: 10 mg or placebo as a material sparing tablet per day for 10 days
Study: NCT03491150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study: NCT01110629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Description: Daily dose: 750-2250mg 3 times a dayfor 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily dose: 3 tablets TID for 8 weeks.
Study: NCT01211028

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Expanded autologous ASCs
Description: Drug: Expanded autologous adipose-derived adult stroma/stem cells
Study: NCT01245855

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: lipo-PGE1
Description: those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
Study: NCT02539875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices
Description: Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices
Description: Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices
Description: Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
Study: NCT01852669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy
Description: Shock wave lithotripsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Study: NCT02456831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 1
Description: method A phytate reduction and 5% protein hydrolysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 2
Description: method A phytate reduction and 10% protein hydrolysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 3
Description: method B phytate reduction and 5% protein hydrolysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control Infant Formula
Description: Ready-to-Feed (RTF) Soy Infant Formula
Study: NCT03915288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group continuous training at moderate intensity
Description: 70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group high Intensity Interval Training
Description: 70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group control
Description: This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
Study: NCT01552538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS System
Description: Stimulation with an active implantable electrical vagal nerve stimulation device